Innovent Biologics Unveils Promising Phase 1 Results for Trispecific Antibody IBI3003 in Relapsed Multiple Myeloma
I'm PortAI, I can summarize articles.
Innovent Biologics announced promising Phase 1 trial results for IBI3003, a trispecific antibody for relapsed multiple myeloma, at the 2025 ASH Annual Meeting. The trial showed favorable tolerability and encouraging efficacy, especially in high-risk patients. The ongoing Phase 1/2 trial is assessing the drug's safety and efficacy in China and Australia.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments